PCN62 Cost-Effectiveness Analysis of First-Line Treatment for Metastatic Renal Cell Carcinoma in Colombia

Value in Health ◽

10.1016/j.jval.2012.03.1179 ◽

2012 ◽

Vol 15 (4) ◽

pp. A219

Author(s):

S.M. Nuñez ◽

J.I. Godoy ◽

A.F. Cardona ◽

J.M. Otero ◽

M. Lujan ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

Metastatic Renal Cell Carcinoma ◽

Cost Effectiveness Analysis ◽

Line Treatment ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text

Cost-Effectiveness Analysis of Using Everolimus or Axitinib in Patients with Metastatic Renal Cell Carcinoma WHO Have Failed to Use of Pazopanib or Sunitinib in First-Line Treatment

Value in Health ◽

10.1016/j.jval.2016.09.2223 ◽

2016 ◽

Vol 19 (7) ◽

pp. A735 ◽

Author(s):

ME Romero Prada ◽

LM Huerfano ◽

NC Roa Cardenas

Keyword(s):

Renal Cell Carcinoma ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

Metastatic Renal Cell Carcinoma ◽

Cost Effectiveness Analysis ◽

Line Treatment ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text

PCN169 COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB FOR THE FIRST-LINE TREATMENT OF ADVANCED/METASTATIC RENAL CELL CARCINOMA IN GREECE

Value in Health ◽

10.1016/j.jval.2019.09.365 ◽

2019 ◽

Vol 22 ◽

pp. S468-S469

Author(s):

F. Diamantogiannis ◽

P. Viktoratos ◽

J. May ◽

B. Malcolm ◽

Van de Wetering G ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

Metastatic Renal Cell Carcinoma ◽

Cost Effectiveness Analysis ◽

Line Treatment ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text

PCN13 COST-EFFECTIVENESS ANALYSIS OF FIRST-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA (MRCC) IN COLOMBIA (ONCOLGROUP STUDY)

Value in Health ◽

10.1016/s1098-3015(10)75340-7 ◽

2009 ◽

Vol 12 (7) ◽

pp. A495 ◽

Author(s):

JI Godoy ◽

AF Cardona ◽

HA Caceres ◽

JM Otero ◽

M Lujan ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

Metastatic Renal Cell Carcinoma ◽

Cost Effectiveness Analysis ◽

Line Treatment ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text

Economic implications of the first-line treatment of advanced renal cell carcinoma in Thailand: A cost-effectiveness analysis.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.e15136 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. e15136-e15136

Author(s):

N. Topibulpong ◽

S. Tanasanvimon ◽

N. Parinyanitikul ◽

C. Vinayanuwattikun ◽

V. Sriuranpong

Keyword(s):

Renal Cell Carcinoma ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

Cost Effectiveness Analysis ◽

Line Treatment ◽

Economic Implications ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text

An updated cost-effectiveness analysis of pazopanib versus sunitinib as first-line treatment for locally advanced or metastatic renal cell carcinoma in Italy

Journal of Medical Economics ◽

10.1080/13696998.2020.1839240 ◽

2020 ◽

pp. 1-9

Author(s):

Stefano Capri ◽

Camillo Porta ◽

Claudia Condorelli ◽

Eleonora Premoli ◽

Ankur Khare ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

Metastatic Renal Cell Carcinoma ◽

Locally Advanced ◽

Line Treatment ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text

A Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Versus Pembrolizumab Plus Axitinib and Versus Avelumab Plus Axitinib in First-Line Treatment of Advanced Renal Cell Carcinoma

Clinical Genitourinary Cancer ◽

10.1016/j.clgc.2021.01.009 ◽

2021 ◽

Author(s):

Rebecca Shay ◽

Andrew Nicklawsky ◽

Dexiang Gao ◽

Elaine T. Lam

Keyword(s):

Renal Cell Carcinoma ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

Cost Effectiveness Analysis ◽

Advanced Renal Cell Carcinoma ◽

Line Treatment ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text

PCN157 COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB + IPILIMUMAB VERSUS SUNITINIB IN THE FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA IN SPAIN

Value in Health ◽

10.1016/j.jval.2019.09.353 ◽

2019 ◽

Vol 22 ◽

pp. S466

Author(s):

C. Polanco Sánchez ◽

F. Pérez-Alcántara ◽

J. May ◽

K.M. Gooden ◽

B. Malcolm ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

Cost Effectiveness Analysis ◽

Line Treatment ◽

Poor Risk ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text

PCN214 COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB VERSUS SUNITINIB FOR THE FIRST-LINE TREATMENT OF INTERMEDIATE- TO POOR-RISK ADVANCED RENAL CELL CARCINOMA IN FRANCE

Value in Health ◽

10.1016/j.jval.2019.09.410 ◽

2019 ◽

Vol 22 ◽

pp. S477

Author(s):

S. Branchoux ◽

S. Négrier ◽

C. de Peretti ◽

B. Malcolm ◽

J. May ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

Cost Effectiveness Analysis ◽

Advanced Renal Cell Carcinoma ◽

Line Treatment ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text

PCN18 ECONOMIC IMPLICATIONS OF THE FIRST-LINE TREATMENT OF ADVANCED RENAL CELL CARCINOMA IN THAILAND: A COST EFFECTIVENESS ANALYSIS

Value in Health ◽

10.1016/s1098-3015(11)73111-4 ◽

2010 ◽

Vol 13 (7) ◽

pp. A513 ◽

Author(s):

N Topibulpong ◽

S Tanasanvimon ◽

N Parinyanitikul ◽

C Vinayanuwattikun ◽

V Sriuranpong

Keyword(s):

Renal Cell Carcinoma ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

Cost Effectiveness Analysis ◽

Line Treatment ◽

Economic Implications ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text

Cost-Effectiveness Analysis of Sunitinib Versus Interferon Alfa for the First-Line Treatment of Advanced And/Or Metastatic Renal Cell Carcinoma in Singapore

Value in Health ◽

10.1016/j.jval.2018.07.110 ◽

2018 ◽

Vol 21 ◽

pp. S15

Author(s):

S Pruis ◽

F Pearce ◽

MI Abdul Aziz ◽

DB Wu ◽

KH Ng

Keyword(s):

Renal Cell Carcinoma ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

Metastatic Renal Cell Carcinoma ◽

Interferon Alfa ◽

Line Treatment ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text